Detalhe da pesquisa
1.
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial.
Arterioscler Thromb Vasc Biol
; 43(8): 1572-1582, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381988
2.
Rivaroxaban in Peripheral Artery Disease after Revascularization.
N Engl J Med
; 382(21): 1994-2004, 2020 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32222135
3.
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
J Vasc Surg
; 77(4): 1107-1118.e2, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36470531
4.
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD.
Circulation
; 144(23): 1831-1841, 2021 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34637332
5.
Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
Circulation
; 144(14): 1104-1116, 2021 10 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34380322
6.
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial.
Am Heart J
; 246: 136-143, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986394
7.
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
Eur Heart J
; 42(39): 4040-4048, 2021 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34430972
8.
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
Circulation
; 142(23): 2219-2230, 2020 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33138628
9.
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.
Am Heart J
; 235: 12-23, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33577800
10.
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD.
Circulation
; 149(19): 1536-1539, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38709838
11.
A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative.
Circulation
; 135(25): 2534-2555, 2017 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28630267
12.
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
Am Heart J
; 199: 83-91, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29754671
13.
A randomized trial of heart failure disease management in skilled nursing facilities (SNF Connect): Lessons learned.
Clin Trials
; 14(3): 308-313, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28135830
14.
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
J Am Coll Cardiol
; 83(17): 1627-1636, 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38658101
15.
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone.
J Thromb Haemost
; 20(5): 1193-1205, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35170216
16.
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization.
JAMA Netw Open
; 5(6): e2215580, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731517
17.
Should Participants in Clinical Trials Be Able to Withdraw from Passive Follow-Up?
Ethics Hum Res
; 43(1): 32-36, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33463078
18.
Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease.
JACC Basic Transl Sci
; 6(2): 174-188, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33665516
19.
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial.
J Am Coll Cardiol
; 78(4): 317-326, 2021 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34010631
20.
Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD.
J Am Coll Cardiol
; 78(18): 1768-1778, 2021 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34711335